UA62784, a novel inhibitor of centromere protein E kinesin-like protein

Meredith C. Henderson, Yeng Jeng Y. Shaw, Hong Wang, Haiyong Han, Laurence H. Hurley, Gary Flynn, Robert T. Dorr, Daniel D. Von Hoff

Research output: Contribution to journalArticlepeer-review

33 Scopus citations


Pancreatic carcinoma is the fourth leading cause of death from cancer. Novel targets and therapeutic options are needed to aid in the treatment of pancreatic cancer. The compound UA62784 is a novel fluorenone with inhibitory activity against the centromere protein E (CENP-E) kinesin-like protein. UA62784 was isolated due to its selectivity in isogenic pancreatic carcinoma cell lines with a deletion of the DPC4 gene. UA62784 causes mitotic arrest by inhibiting chromosome congression at the metaphase plate likely through inhibition of the microtubule-associated ATPase activity of CENP-E. Furthermore, CENP-E binding to kinetochores duringmitosis is not affected by UA62784, suggesting that the target lies within the motor domain of CENP-E. UA62784 is a novel specific inhibitor of CENP-E and its activity suggests a potential role for antimitotic drugs in treating pancreatic carcinomas.

Original languageEnglish (US)
Pages (from-to)36-44
Number of pages9
JournalMolecular Cancer Therapeutics
Issue number1
StatePublished - Jan 1 2009

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'UA62784, a novel inhibitor of centromere protein E kinesin-like protein'. Together they form a unique fingerprint.

Cite this